Nuvalent
NUVL
NUVL was delisted on the 14th of July, 2026.
110 hedge funds and large institutions have $2.33B invested in Nuvalent in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 37 increasing their positions, 33 reducing their positions, and 8 closing their positions.
5,275% more call options, than puts
Call options by funds: $215K | Put options by funds: $4K
263% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 8
65% more capital invested
Capital invested by funds: $1.41B → $2.33B (+$920M)
24% more funds holding
Funds holding: 89 → 110 (+21)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
12% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 33
1.86% more ownership
Funds ownership: 105.68% → 107.54% (+1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$42.4M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$10.3M |
| 3 |
BlackRock
New York
|
+$7.6M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$5.22M |
| 5 |
State Street
Boston,
Massachusetts
|
+$4.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$14.4M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$10.9M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$6.84M |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$6.29M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.68M |
NUVL Hedge Fund Activity: Q2 2023 in Review
110 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Nuvalent (NUVL) for Q2 2023, worth a combined $2.33B — up 65% from $1.41B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new NUVL positions and 8 closed out — a net gain of 21 holders — while 37 added to existing stakes and 33 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $42.4M. The largest seller was JP Morgan Chase, cutting an estimated $14.4M.
- 110 institutional investors held Nuvalent (NUVL) as of Q2 2023, up from 89 in Q1 2023.
- Funds reported $2.33B of Nuvalent stock for Q2 2023, up 65% quarter-over-quarter.
- 29 funds opened new Nuvalent positions in Q2 2023 and 8 closed out, a net change of +21 holders.
- The largest Nuvalent buyer in Q2 2023 was Paradigm Biocapital Advisors, an estimated $42.4M added.
- The largest Nuvalent seller in Q2 2023 was JP Morgan Chase, an estimated $14.4M sold.
Based on aggregated 13F filings for Q2 2023.